Insurers Sued for Refusing to Pay for Expensive Hep C Drugs

Source: Seattle Times

Feb 04, 2016

Class action lawsuits allege that two Washington state insurers — Group Health and BridgeSpan insurance — are unfairly limiting use of hepatitis C drugs due to cost.

The high price tags on direct-acting antivirals, such as Gilead’s Sovaldi and Harvoni, prompted many state Medicaid programs and private insurers to restrict use only to people with the most severe liver scarring.

However, the American Association for the Study of Liver Diseases recently updated its guidelines to indicate that the new direct-acting antivirals would benefit nearly all patients infected with HCV. According to Ele Hamburger, one of the lawyers involved in the suits, "If the new hep C drugs are now the standard for medical care, they should be provided to all patients and not rationed to a few."

Read the Seattle Times article 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments